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PANEL I DISCUSSION
MR. SILKENAT: I have a question for Joe Velli. I have
some feeling for what kinds of changes Jim Cochrane and the
New York Stock Exchange might want to make. But, from The
Bank of New York's perspective in dealing with so many foreign
companies on a daily basis, what regulatory changes would you
make if you could be the one to make the decision today or to-
morrow to move the market along, to give easier access to these
companies?
MR. VELLI: We are in basic agreement that the best way to
approach it is by taking these world-class issuers and making
them exempt or subject to less accounting and disclosure re-
quirements. We think that is probably the best way to go, this
world-class issuer concept that Jim Cochrane explained, where
you take the top 300 or 500 companies and, if they want to, en-
able them to list in the U.S. without conforming to U.S. account-
ing or disclosure.
QUESTION: I have a question for Mr. Jensen on 144A.
Would you expand a little on the interaction of Regulation S
with Rule 144A? In a recent case, it is pointed out that securities
sold under 144A are restricted securities and cannot be sold
within the U.S. public market for the two years because they
were specifically made 144A restricted securities. That rule was
modified a little bit to allow a two-year holding period. But, I
think, the philosophy of 144A was to create a marketplace for
great, big institutions that do not need the protection of the se-
curities law but for the anti-fraud provisions. How does that
mesh with your notes on interfacing with Regulation S?
MR. JENSEN: Regulation S is, in fact, itself a safe harbor for
issues outside the United States, but it provides specifically that
144A securities can be issued in the United States simultaneously
with an extraterritorial, outside-the-U.S. offering.
MR. VELLI: To QIBs. Outside the U.S. they could be of-
fered to anybody.
QUESTION: Simultaneously in the United States?
MR. JENSEN: QIBs in the United States, anybody outside,
as long as you stay within the Regulation S safe harbor. And I
think there is probably some concern about flowback of the Reg-
ulation S securities into the U.S. market, but there are also pro-
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cedures to prevent that, specific procedures under Regulation S.
So the two should work together, and in fact do work together.
QUESTION: But the concern in the question I had would
be on your point that securities purchased in the United States
under 144A can be resold outside the United States. Let's pick
for a scenario a QIB, California State Teachers Pension Fund,
that buys bonds that are over 40 days old. They could certainly
sell them to Metropolitan Life in the United States. But the trad-
ing desk of the pension fund works this for ten or fifteen min-
utes, gives up, calls a broker and says, "Blow this overseas." On
Day 41, the 144A paper is sold to anybody under Regulation S -
let's say, a Zurich money manager or a high-net-worth individual
in Hong Kong. That seems to be fine. Day 42, the Hong Kong
purchaser, under Regulation S, sells it to a widow in Kansas or an
orphan in New York City. That's not two years.
MR. VELLI: As long as the security overseas is seasoned, it
can come back into the U.S. That's the way Regulation S works.
MR. JENSEN: But if it's Day 42, there is theoretically indi-
rect distribution in the United States.
QUESTION: Well, 40 days is your bond period. So, if the
U.S. institution blows it out overseas on Day 41, then, theoreti-
cally, they can come into the public market on Day 42, thus elim-
inating the whole rationale that 144A securities cannot get into
the U.S. marketplace for two years.
MR. VELLI: But as long as that security sold under Regula-
tion S outside is done through a legitimate transaction on an
exchange ....
QUESTION: It could be 48 hours.
MR. VELLI: Exactly. Even if there was no 144A compo-
nent, if a company just made a foreign offering, after a season-
ing period, U.S. investors could buy those shares or debt directly
anyway.
QUESTION: I'm more concerned about it coming back
into the public market.
MR. VELLI: But it comes back into the public market. If a
U.S. investor buys it directly in Europe, it comes back in.
QUESTION: Could any of you comment on what the typi-
cal foreign issuer is that you would advise to go for a direct list-
ing of stock versus American Depositary Receipt?
MR. DECKER: I guess one quick answer to that, if I under-
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stand your question correctly, the ADR may be used in all private
placement listings or offerings. It's not a question of whether
you would use the ADR. The question is at what point you would
be well advised as a company to do a listing versus an offering.
I guess the short answer I would give is what I said before.
That is, if there is no burning need right now to raise funds in
the U.S. markets, but you would view the listing as an initial step
toward keeping your options open to do that in the future, I
think that yours is the kind of company where it makes sense to
consider the listing alternative versus the public offering.
MR. VELLI: There is an awful lot of confusion about this.
In fact, I am told almost every day, "We don't want to list our
ADRs in the United States; we want to list our shares." The fact
of the matter is that, excluding Canada, non-U.S. companies -
as Jim Cochrane said, they are looking at the possibility of direct
listings - but right now, if a non-U.S. company wants to list in
the United States, they have to use ADRs. There really isn't a
choice.
There have been a few Chinese companies who have
formed shell companies in Bermuda and then listed their shares,
not ADRs, directly in the United States. There have been a
couple of other cases where European companies have done
that. But they're not listing the company; they are forming a
separate company and listing that company. Essentially, they are
listing a U.S. company in the U.S. marketplace. Everywhere else
- France, Spain, Italy - they all use ADRs.
Even in the event the New York Stock Exchange does invent
a better mousetrap from a trading standpoint, there are a lot of
other obstacles that have to be overcome as well. A lot of U.S.
pension funds, a lot of U.S. investment managers, legally must
invest in ADRs when they are investing in non-U.S. securities.
So we would be all for it if the New York Stock Exchange
could invent a better mousetrap, because there is still going to
be some role in there for The Bank of New York as transfer
agent, etc. But right now, and I would say for the foreseeable
future, the only workable solution is for a company to use ADRs.
MR. COCHRANE: Just so I'm not misunderstood on that
particular item, we went out and did a fair amount of surveying.
There is anecdotal evidence in the securities industry that there
is an enormous appetite to trade foreign securities in ordinary
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form in their own local currencies. We surveyed that to death,
and it is not true. It is going to be true someday, but someday is
pretty far out there.
MR. VELLI: So, for the foreseeable future, ADRs are the
way to list. In fact, from a practical standpoint, it's the only way
to list in the U.S.
QUESTION: There is a high transactional cost for this
question for coming to the front. The question is to all of the
panelists. Does a foreign company really have to come to the
United States to raise U.S. capital, or can a foreign company
raise U.S. capital through, for example, B shares? It seems that
none of the panelists has mentioned that. As I am aware, there
might be an issuing of specific U.S. shares in a local stock ex-
change, like the London Stock Exchange.
MR. VELLI: Real easy - if the company doesn't register
here for a public deal, they're not going to be able to raise capi-
tal here. Yes, these B share companies in China, even though
they trade in U.S. dollars or in Hong Kong dollars in China,
when they do their offerings they cannot come and attract U.S.
capital without registering here in the United States.
Now, there are some pension funds, like Fidelity, who have
overseas operations, and in some ways could be treated as a non-
U.S. investor because they're incorporated outside the United
States; they would be able to buy it. But a true U.S. investor
would not be able to take up that offering.
QUESTION: You discussed some of the high-end compa-
nies. Not to turn it into a ghetto, but can you give me some
sense of what the requirements are and what would be the mini-
mum size of a foreign company that would be able to gain en-
trance to the U.S. markets?
MR. VELLI: It all depends on what type of transaction
we're talking about.
QUESTION: Primarily 144A.
MR. VELLI: 144A is not typically going to be worth the ef-
fort, from the cost standpoint, if they're looking at raising less
than U.S.$20 to U.S.$25 million. There have been some smaller
deals. On the up-side, there have been deals for U.S.$500 mil-
lion and more. But typically, 144A deals are somewhere be-
tween, I would say, U.S.$25 million and U.S.$75 million. Once
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you start getting bigger than that, it's more advantageous proba-
bly to go the public route.
QUESTION: I am working on a paper right now looking at
ADRs. There seems to be a considerable under-pricing of ADRs.
For example, take the case of Royal Dutch Petroleum versus Ex-
xon. Royal Dutch seems to be selling at a much higher ratio to
book value; it seems to have a higher return on equity invest-
ment; and yet, it has been priced much lower to book value than
Exxon. And you find the same thing is true for Glaxo versus, say,
Merck.
We are finding actually that the accounting method se-
lected seems to have some role in this under-pricing. Are there
any other reasons that you can think of? One possibility could
be foreign exchange risk, as was pointed out by Mr. Cochrane.
However, that doesn't seem to play that great a role simply be-
cause, to go back to his example, if the pound basically was de-
valued, what would happen? What are the other factors that
lead to this consistent under-pricing of ADRs?
MR. VELLI: I think one of the key elements is that it's still a
non-U.S. company, and in most cases, even though there are ex-
ceptions, the home market is still going to be the primary factor
in dictating how the company is valued. Again, you take the
drug companies or the telecommunications companies, where
the typical telecom company in the U.S. would have a higher P/
E than a typical telecom company in Europe. What we have seen
is, for argument's sake, if the P/E ratio is ten in France and fif-
teen in the U.S., when the company is moved to the U.S., it will
get a higher valuation overall, but it will not go all the way up to
the U.S. standard. That's because the home market is really still
where 70% or 80% of the liquidity in trading takes place.
QUESTION: I have a question about the confidentiality of
filings. I guess the issue plan is confidential. What is the policy
of the SEC? Does it evaluate whether eventually everything will
be disclosed, or is there sort of negotiation going on between the
SEC and the issuer as to what information has to be disclosed?
MR. DECKER: Let me say a few words about that. The idea
of a confidential filing is an accommodation that the SEC does
provide to non-U.S. issuers fairly routinely. It's almost unheard
of for U.S. registrants, but very routine for foreign registrants.
It's part of this process that we have talked about, of the SEC
[Vol. 17:S68
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trying to work with companies that are having difficulty with the
process.
What they will basically do is put that document through a
fairly thorough review, even though it's not an official filing and
may have some of the required information missing. From the
financial statement perspective, which I can speak of, these doc-
uments are thoroughly reviewed so that the company can make a
determination of how much more they are going to need to do
to complete that filing and to get it to the point where it is ac-
ceptable to the SEC.
There are lots of different reasons why companies do confi-
dential filings, but that's one of them, to get most of the substan-
tive issues out in the open before they officially file the registra-
tion statement, where it would be a matter of public record.
MR. SILKENAT: Let me just follow up. For me, the experi-
ence has been a very good one. The SEC has responded in
terms of raising good questions and it has been a very useful
dialogue. But I think you ought to follow up on that question
with Richard Kosnik to get his feel for how the SEC is going to
be looking at these issues in the future.
QUESTION: In your opinion, has Regulation S really been
serving its purpose? Has it increased the attractiveness of the
U.S. securities markets, or is it only in conjunction with 144A
that it has?
MR. VELLI: In my experience, it has been in conjunction
with 144A. These companies would not be doing these 144As if
they couldn't rely on Regulation S.
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